Wegovy GLP1 Diet Principles Effects Side Effects

There is a lot of talk about the diet injection Wegovy along the lines of "just get the shot and you'll lose weight," but in the clinic, quite a few people misunderstand exactly what this drug is and whom it is for. Wegovy is not a simple appetite suppressant but a prescription medicine that mimics the action of the GLP-1 hormone our body originally secretes. In this article, I will calmly organize, leaning on credible evidence, how Wegovy works, for what indications it is approved, and what effects and side effects are reported in clinical studies. Topics such as comparison with other drugs or use in menopause are covered in separate articles; here I focus on the mechanism and indications of the drug Wegovy itself.

Wegovy's main ingredient, semaglutide, is a substance designed to imitate our body's GLP-1 (Glucagon-Like Peptide-1) hormone. GLP-1 is a hormone secreted mainly in the small intestine when food is eaten, and some is also made in the brainstem and pancreas. Normally it is secreted and then rapidly broken down within a few minutes, but Wegovy is a drug whose structure has been changed so that, while acting similarly to this hormone, it breaks down slowly in the body, so that the effect continues with a once-weekly injection.

It is commonly known only as a "shot that suppresses appetite," but its range of action is broader than that. GLP-1-class drugs originally started in type 2 diabetes treatment and were used as blood-sugar regulators, then expanded their territory to anti-obesity drugs as the weight-loss effect was confirmed. In other words, it is important to first understand that Wegovy is a drug that uses a hormone pathway involved not only in appetite but in blood sugar and metabolism overall.

Wegovy's core principle lies in regulating our body's gut–brain–pancreas axis simultaneously. Because it acts in three branches rather than touching only one place, appetite control and metabolic improvement can appear together.

The action at each organ can be summarized as follows.

The explanation I often give patients in the clinic is that Wegovy works in a way that "makes you eat less while also emptying slowly, and meanwhile soothes blood sugar too." Because the stomach empties slowly, satiety after a meal lasts long, and in the brain the craving signal for food decreases. However, this very "delayed gastric emptying" also becomes the cause of early discomfort such as the nausea covered later. It is good to keep in mind together that the effect and the side effects come from the same mechanism.

Wegovy is not a drug anyone uses lightly for cosmetic purposes, but an anti-obesity drug with clear indications. The US Food and Drug Administration (FDA) approved Wegovy (semaglutide 2.4mg) for chronic weight management in 2021, and its targets are distinguished by body mass index (BMI).

The approved indications can be summarized as follows.

• Obese adults with a BMI of 30 or higher
• Adults with a BMI of 27 or higher who have at least one weight-related comorbidity such as hypertension, type 2 diabetes, or hyperlipidemia
• In both cases above, used as adjunctive therapy combined with a low-calorie diet and increased physical activity

As noted in the original article, it is reported to be helpful in cases where controlling meal portions is difficult and there are binge-eating and late-night-eating habits, or where the effect was limited even with diet and exercise combined. Also, in 2024 an additional indication was approved for lowering the risk of cardiovascular events in adults who are obese or overweight and have cardiovascular disease (FDA, 2024).

Conversely, if it is for a cosmetic purpose within the normal weight range of simply "wanting to lose just a few kg," it does not fit the indications. Whether you fall within Wegovy's target must be considered together with BMI, comorbidities, and history, so if weight gain is a concern, the order is to start by checking the cause of weight gain. If you are curious about which category you are close to, get a consultation on Wegovy indications

Wegovy's weight-loss effect has been reported through large-scale clinical studies. The most widely cited is the STEP clinical study program, of which the STEP 1 study was conducted over 68 weeks targeting about 2,000 obese and overweight adults (NEJM, 2021).

In this study, the group given semaglutide 2.4mg once weekly showed clear weight reduction compared to the placebo group, with double-digit percentage weight loss reported on average. In the subsequent STEP 5 study, a pattern of maintained weight loss was observed even with long-term administration over about 2 years (NEJM, 2022). However, I want to emphasize that these figures are average values that came out under clinical-trial conditions combined with diet and exercise, and that there can be individual differences.

The changes mentioned in the original article—namely, reduction of visceral fat and abdominal circumference, improvement of blood sugar, triglycerides, and blood pressure, and the easing of binge-eating and late-night-eating habits as cravings for food decrease—have also been reported together in such studies. However, it cannot be asserted that the same magnitude of change appears in everyone. In clinical experience, even with the same drug the degree of response differs from person to person, and the result varies depending on eating habits, activity level, and comorbidities. The accurate understanding is not "if you get the shot you will unconditionally lose weight" but "the effect is added on top of a foundation of diet and exercise."

Wegovy is a drug you must clearly know the side effects of, as much as the effects, before starting. The most common are gastrointestinal-related symptoms such as nausea, vomiting, diarrhea, and constipation. Because of the delayed gastric emptying action explained earlier, especially in the early period of administration or when increasing the dose, some people complain of a bloated and stuffy feeling (NEJM, 2021).

The side effects to be careful of can be summarized as follows.

• Common symptoms: nausea, vomiting, diarrhea, constipation, temporary loss of appetite
• Rare but requiring caution: pancreatitis, gallstones, decreased kidney function
• Risk of hypoglycemia when taking diabetes medication together

Also, those falling under the following should be cautious about use: those who are pregnant or breastfeeding, those allergic to GLP-1 analogs, and those with serious gastrointestinal disease or a history of pancreatitis. The process of checking such side effects and contraindications in advance and managing the dose by raising it slowly is the key to safe use. Rather than vaguely fearing side effects themselves, it is more helpful to distinguish which symptoms are a normal adaptation process and which signals require medical care.

There is a clear reason for slowly increasing Wegovy as prescribed. Rather than using the maintenance dose of 2.4mg from the start, you begin at a low dose and raise it stepwise at intervals of a few weeks (per the FDA label, as of 2023). The biggest purpose of doing this is to reduce gastrointestinal side effects such as nausea.

In the clinic, there are people who, unable to endure the early discomfort, stop the drug on their own, or conversely try to arbitrarily raise the dose to see the effect quickly. Neither is recommended. The rate of increase and the dose reached must be adjusted according to the individual's response and tolerability, and this judgment is the role of the prescribing medical staff. If side effects are severe, the rate of increase can be slowed or the maintenance dose adjusted, so it is safer to tell us at the visit about uncomfortable symptoms rather than enduring them.

One more thing to say honestly is that Wegovy is not a drug you get once for life and are done with, but is closer to a drug that manages the chronic disease of obesity. It is good to plan the weight change upon stopping the drug and the maintenance strategy together from before starting. If you are curious about diet injections overall, please also refer to how the diet injection (GLP-1) works and the explanation of rebound after stopping.

Wegovy is a prescription medicine that regulates our body's gut–brain–pancreas axis to soothe weight and metabolic health together. Although meaningful effects have been reported in clinical studies, since it is a drug with clear indications, side effects, and contraindications, it is not appropriate to regard it as an "all-purpose diet shot that works well for anyone." Because effects and side effects differ depending on the individual's BMI, comorbidities, and history, the diagnosis and tailored management of professional medical staff are needed. If you are hesitant about whether to start, look at the GLP-1 diet injection guide, or get a consultation on a Wegovy prescription

Written by: Lee Dong-hee Director · Obstetrics and Gynecology Specialist · View medical staff profile

First published August 14, 2025 · Last reviewed May 30, 2026

References: U.S. FDA Wegovy approval information (2021, 2024), STEP 1 clinical study NEJM (2021), STEP 5 clinical study NEJM (2022), Wegovy FDA product label (2023)

This article is intended to provide general health information and does not replace individual diagnosis or treatment. If you have symptoms, please consult through a medical visit.